A Randomized Double-Blind Trial to Evaluate the Efficacy and Safety of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
Latest Information Update: 04 Jul 2025
At a glance
- Drugs CAL 101 Calluna Pharma (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms AURORA
- Sponsors Calluna Pharma
Most Recent Events
- 26 Jun 2025 Status changed from not yet recruiting to recruiting.
- 23 Dec 2024 New trial record